ArticleAntimicrobial agents and chemotherapy2016
Neomycin Sulfate Improves the Antimicrobial Activity of Mupirocin-Based Antibacterial Ointments.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- From Natural Product to Topical Antimicrobial Candidate: EvaluatingPharmaceuticals (Basel, Switzerland) · 2026Article
- Iron(III)-Tropolone Complex as a Topical Agent Against Drug-Resistant MRSA Skin Infections.Antibiotics (Basel, Switzerland) · 2026Article
- Synergistic activity of mupirocin in combination with protocatechuic acid ethyl ester against mupirocin-resistant MRSA.Frontiers in cellular and infection microbiology · 2026Article
- Salivary gland tissue chip screening identifies candidate radioprotective drugs.Communications medicine · 2025Article
- Crystallization of neomycin nanoparticles in the presence of polyvinyl pyrrolidone (PVP).Nanoscale advances · 2025Article
- Article
- Harnessing the Dual Antimicrobial Mechanism of Action with Fe(8-Hydroxyquinoline)Antibiotics (Basel, Switzerland) · 2023Article
- Inhibition of Erythromycin and Erythromycin-Induced Resistance amongAntibiotics (Basel, Switzerland) · 2023Article
- Combinational System of Lipid-Based Nanocarriers and Biodegradable Polymers for Wound Healing: An Updated Review.Journal of functional biomaterials · 2023Review
- Integrating LC-MS and HS-GC-MS for the metabolite characterization of the Chinese medicinal plantFrontiers in nutrition · 2023Article
- Tea Tree Oil Nanoemulsion-Based Hydrogel Vehicle for Enhancing Topical Delivery of Neomycin.Life (Basel, Switzerland) · 2022Article
- Silk Fibroin-Based Therapeutics for Impaired Wound Healing.Pharmaceutics · 2022Review
- A Modular Synthetic Route InvolvingJournal of medicinal chemistry · 2021Article
- Article
- Optimization of 2-Acylaminocycloalkylthiophene Derivatives for Activity againstAntibiotics (Basel, Switzerland) · 2021Article
- Discovery ofMicroorganisms · 2021Article
- A New Promising Anti-Infective Agent Inhibits Biofilm Growth by Targeting Simultaneously a Conserved RNA Function That Controls Multiple Genes.Antibiotics (Basel, Switzerland) · 2021Article
- Small-Molecule Antibiotics Inhibiting tRNA-Regulated Gene Expression Is a Viable Strategy for Targeting Gram-Positive Bacteria.Antimicrobial agents and chemotherapy · 2020Article
- Tackling Antibiotic Resistance with Compounds of Natural Origin: A Comprehensive Review.Biomedicines · 2020Review
- Iron Sequestrant DIBI, a Potential Alternative for Nares Decolonization of Methicillin-Resistant Staphylococcus aureus, Is Anti-infective and Inhibitory for Mupirocin-Resistant Isolates.Antimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
In the midst of the current antimicrobial pipeline void, alternative approaches are needed to reduce the incidence of infection and decrease reliance on last-resort antibiotics for the therapeutic intervention of bacterial pathogens. In that regard, mupirocin ointment-based decolonization and wound maintenance practices have proven effective in reducing Staphylococcus aureus transmission and mitigating invasive disease. However, the emergence of mupirocin-resistant strains has compromised the agent's efficacy, necessitating new strategies for the prevention of staphylococcal infections. Herein, we set out to improve the performance of mupirocin-based ointments. A screen of a Food and Drug Administration (FDA)-approved drug library revealed that the antibiotic neomycin sulfate potentiates the antimicrobial activity of mupirocin, whereas other library antibiotics did not. Preliminary mechanism of action studies indicate that neomycin's potentiating activity may be mediated by inhibition of the organism's RNase P function, an enzyme that is believed to participate in the tRNA processing pathway immediately upstream of the primary target of mupirocin. The improved antimicrobial activity of neomycin and mupirocin was maintained in ointment formulations and reduced S. aureus bacterial burden in murine models of nasal colonization and wound site infections. Combination therapy improved upon the effects of either agent alone and was effective in the treatment of contemporary methicillin-susceptible, methicillin-resistant, and high-level mupirocin-resistant S. aureus strains. From these perspectives, combination mupirocin-and-neomycin ointments appear to be superior to that of mupirocin alone and warrant further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.